Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
Sponsor: Beacon Therapeutics
Summary
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.
Official title: A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Key Details
Gender
All
Age Range
4 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2017-08-03
Completion Date
2026-08
Last Updated
2022-07-22
Healthy Volunteers
No
Conditions
Interventions
AGTC-402
AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
Locations (6)
VitreoRetinal Associates
Gainesville, Florida, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Cincinnati Eye Institute
Cincinnati, Ohio, United States
Casey Eye Institute, Oregon Health and Sciences University
Portland, Oregon, United States
Hadassah-Hebrew University Medical Center
Jerusalem, Israel